Unique ID issued by UMIN | UMIN000006730 |
---|---|
Receipt number | R000007949 |
Scientific Title | Heat Shock Protein 105 (HSP105) peptide-pulsed dendritic cell vaccination therapy for patients with advanced/ recurrent cancer. |
Date of disclosure of the study information | 2011/11/15 |
Last modified on | 2014/11/25 11:50:39 |
Heat Shock Protein 105 (HSP105) peptide-pulsed dendritic cell vaccination therapy for patients with advanced/ recurrent cancer.
HSP105 peptide-pulsed dendritic cell vaccination therapy for advanced/ recurrent cancer.
Heat Shock Protein 105 (HSP105) peptide-pulsed dendritic cell vaccination therapy for patients with advanced/ recurrent cancer.
HSP105 peptide-pulsed dendritic cell vaccination therapy for advanced/ recurrent cancer.
Japan |
Advanced/recurrent cancer
(pancreatic cancer, colon cancer, biliary tract cancer, esophageal cancer, pharynx cancer, breast cancer etc.)
Gastrointestinal surgery | Hepato-biliary-pancreatic surgery | Breast surgery |
Urology |
Malignancy
NO
To investigate safety and efficacy of HSP105 peptide-pulsed dendritic cell vaccination therapy.
Safety,Efficacy
Exploratory
Pragmatic
Not applicable
Safety
Immunological responses
Antitumor effect
Overall survival
Progression-free survival
Interventional
Single arm
Non-randomized
Open -no one is blinded
Historical
1
Treatment
Vaccine | Maneuver |
HSP105 peptide-pulsed dendritic cells are injected on day
20 | years-old | <= |
Not applicable |
Male and Female
1) Age >= 20 years at informed consent.
2) Patients who recognized HSP105 expression on tumor tissue.
3) HLA-A*24:02, 02:01, 02:06 or 02:07 positive.
4) Performance status is 0-1.
5) No serious abnormality in heart, lung, bone marrow, liver, and renal functions.
1) Pulmonary fibrosis or interstitial pneumonia, including their history or predisposition;
2) Serious drug allergy;
3) Difficult infections to control;
4) Serious cardiac disease;
5) Active autoimmune diseases;
6) Other cancers;
7) Continuous systemic administration of steroids and/or immunosuppressants within 4 weeks.
19
1st name | |
Middle name | |
Last name | Norihiro Kokudo |
The University of Tokyo Hospital
Hepato-Biliary-Pancreatic Surgery Division, Artificial Organ and Transplantation Surgery Division
7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, Japan
1st name | |
Middle name | |
Last name | Kazuhiro Kakimi |
The University of Tokyo Hospital
Department of Immunotherapeutics
7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, Japan
03-5805-3161
immunotherapy-admin@umin.ac.jp
The University of Tokyo Hospital
Medinet Co.,Ltd.
Profit organization
Japan
NO
2011 | Year | 11 | Month | 15 | Day |
Partially published
Completed
2011 | Year | 10 | Month | 03 | Day |
2011 | Year | 11 | Month | 01 | Day |
2014 | Year | 09 | Month | 30 | Day |
2011 | Year | 11 | Month | 15 | Day |
2014 | Year | 11 | Month | 25 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007949
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |